RU2762279C2 - Замещенные пиразолоазепин-4-оны и их применение в качестве ингибиторов фосфодиэстеразы - Google Patents
Замещенные пиразолоазепин-4-оны и их применение в качестве ингибиторов фосфодиэстеразы Download PDFInfo
- Publication number
- RU2762279C2 RU2762279C2 RU2019121006A RU2019121006A RU2762279C2 RU 2762279 C2 RU2762279 C2 RU 2762279C2 RU 2019121006 A RU2019121006 A RU 2019121006A RU 2019121006 A RU2019121006 A RU 2019121006A RU 2762279 C2 RU2762279 C2 RU 2762279C2
- Authority
- RU
- Russia
- Prior art keywords
- tetrahydropyran
- ethyl
- pyrazolo
- dihydro
- oxospiro
- Prior art date
Links
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 title 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 title 1
- -1 cyano, hydroxyl Chemical group 0.000 claims abstract description 645
- 150000001875 compounds Chemical class 0.000 claims abstract description 359
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 197
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 120
- 239000001257 hydrogen Substances 0.000 claims abstract description 120
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 84
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 70
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract description 70
- 125000001424 substituent group Chemical group 0.000 claims abstract description 58
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract description 56
- 150000002367 halogens Chemical class 0.000 claims abstract description 54
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 47
- 150000003839 salts Chemical class 0.000 claims abstract description 44
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 43
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims abstract description 40
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims abstract description 40
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 39
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 37
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 36
- 201000010099 disease Diseases 0.000 claims abstract description 26
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 23
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 23
- 238000011282 treatment Methods 0.000 claims abstract description 23
- 208000035475 disorder Diseases 0.000 claims abstract description 21
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims abstract description 20
- 125000003566 oxetanyl group Chemical group 0.000 claims abstract description 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 17
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 12
- 208000017520 skin disease Diseases 0.000 claims abstract description 12
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims abstract description 9
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 9
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 6
- 229940095102 methyl benzoate Drugs 0.000 claims description 80
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 62
- 150000002431 hydrogen Chemical class 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 49
- 201000004624 Dermatitis Diseases 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 23
- 206010040799 Skin atrophy Diseases 0.000 claims description 15
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 claims description 14
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 13
- 201000008937 atopic dermatitis Diseases 0.000 claims description 13
- FNJPHLBTJIHHPG-UHFFFAOYSA-N 2-(2-cyanophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=CC=C1C#N FNJPHLBTJIHHPG-UHFFFAOYSA-N 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 201000004681 Psoriasis Diseases 0.000 claims description 10
- 208000004631 alopecia areata Diseases 0.000 claims description 10
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 9
- 208000003251 Pruritus Diseases 0.000 claims description 9
- 206010000496 acne Diseases 0.000 claims description 9
- 208000010668 atopic eczema Diseases 0.000 claims description 9
- LPNBBFKOUUSUDB-UHFFFAOYSA-M p-toluate Chemical compound CC1=CC=C(C([O-])=O)C=C1 LPNBBFKOUUSUDB-UHFFFAOYSA-M 0.000 claims description 9
- 206010012442 Dermatitis contact Diseases 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 206010051246 Photodermatosis Diseases 0.000 claims description 8
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 8
- 208000024780 Urticaria Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 208000010247 contact dermatitis Diseases 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 230000008845 photoaging Effects 0.000 claims description 8
- 230000002062 proliferating effect Effects 0.000 claims description 8
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 8
- 150000003431 steroids Chemical class 0.000 claims description 8
- 201000004384 Alopecia Diseases 0.000 claims description 7
- 231100000360 alopecia Toxicity 0.000 claims description 7
- 230000009759 skin aging Effects 0.000 claims description 7
- BZSXEZOLBIJVQK-UHFFFAOYSA-M 2-methylsulfonylbenzoate Chemical compound CS(=O)(=O)C1=CC=CC=C1C([O-])=O BZSXEZOLBIJVQK-UHFFFAOYSA-M 0.000 claims description 6
- CHZPJUSFUDUEMZ-UHFFFAOYSA-M 3-acetylbenzoate Chemical compound CC(=O)C1=CC=CC(C([O-])=O)=C1 CHZPJUSFUDUEMZ-UHFFFAOYSA-M 0.000 claims description 6
- NSGKIIGVPBTOBF-UHFFFAOYSA-M 3-fluoro-5-(trifluoromethyl)benzoate Chemical compound [O-]C(=O)C1=CC(F)=CC(C(F)(F)F)=C1 NSGKIIGVPBTOBF-UHFFFAOYSA-M 0.000 claims description 6
- NAETXYOXMDYNLE-UHFFFAOYSA-N 3-sulfamoylbenzoic acid Chemical compound NS(=O)(=O)C1=CC=CC(C(O)=O)=C1 NAETXYOXMDYNLE-UHFFFAOYSA-N 0.000 claims description 6
- BFTPXPCTGHARJF-UHFFFAOYSA-M 4-(morpholine-4-carbonyl)benzoate Chemical compound C1=CC(C(=O)[O-])=CC=C1C(=O)N1CCOCC1 BFTPXPCTGHARJF-UHFFFAOYSA-M 0.000 claims description 6
- SWKPKONEIZGROQ-UHFFFAOYSA-M 4-(trifluoromethyl)benzoate Chemical compound [O-]C(=O)C1=CC=C(C(F)(F)F)C=C1 SWKPKONEIZGROQ-UHFFFAOYSA-M 0.000 claims description 6
- UCAGLBKTLXCODC-UHFFFAOYSA-M 4-sulfamoylbenzoate Chemical compound NS(=O)(=O)C1=CC=C(C([O-])=O)C=C1 UCAGLBKTLXCODC-UHFFFAOYSA-M 0.000 claims description 6
- XSIFPSYPOVKYCO-UHFFFAOYSA-N benzoic acid butyl ester Natural products CCCCOC(=O)C1=CC=CC=C1 XSIFPSYPOVKYCO-UHFFFAOYSA-N 0.000 claims description 6
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 claims description 5
- PPHHAZOVVZBSCM-UHFFFAOYSA-M 4-chloro-3-(trifluoromethyl)benzoate Chemical compound [O-]C(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 PPHHAZOVVZBSCM-UHFFFAOYSA-M 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- BKYWPNROPGQIFZ-UHFFFAOYSA-M 2,4-dimethylbenzoate Chemical compound CC1=CC=C(C([O-])=O)C(C)=C1 BKYWPNROPGQIFZ-UHFFFAOYSA-M 0.000 claims description 3
- FBRJYBGLCHWYOE-UHFFFAOYSA-N 2-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(F)(F)F FBRJYBGLCHWYOE-UHFFFAOYSA-N 0.000 claims description 3
- OCIYTBZXTFPSPI-UHFFFAOYSA-M 2-fluoro-4-(trifluoromethyl)benzoate Chemical compound [O-]C(=O)C1=CC=C(C(F)(F)F)C=C1F OCIYTBZXTFPSPI-UHFFFAOYSA-M 0.000 claims description 3
- LIFKXWNFWIUMJT-UHFFFAOYSA-M 2-fluoro-5-(trifluoromethyl)benzoate Chemical compound [O-]C(=O)C1=CC(C(F)(F)F)=CC=C1F LIFKXWNFWIUMJT-UHFFFAOYSA-M 0.000 claims description 3
- OPVAJFQBSDUNQA-UHFFFAOYSA-M 3,4-dimethylbenzoate Chemical compound CC1=CC=C(C([O-])=O)C=C1C OPVAJFQBSDUNQA-UHFFFAOYSA-M 0.000 claims description 3
- FQXQBFUUVCDIRK-UHFFFAOYSA-M 3-(trifluoromethyl)benzoate Chemical compound [O-]C(=O)C1=CC=CC(C(F)(F)F)=C1 FQXQBFUUVCDIRK-UHFFFAOYSA-M 0.000 claims description 3
- AHFINSWGYAZBOZ-UHFFFAOYSA-N 4-chloro-2-(trifluoromethyl)benzaldehyde Chemical group FC(F)(F)C1=CC(Cl)=CC=C1C=O AHFINSWGYAZBOZ-UHFFFAOYSA-N 0.000 claims description 3
- JUHPDXOIGLHXTC-UHFFFAOYSA-M 4-fluoro-2-(trifluoromethyl)benzoate Chemical compound [O-]C(=O)C1=CC=C(F)C=C1C(F)(F)F JUHPDXOIGLHXTC-UHFFFAOYSA-M 0.000 claims description 3
- WZBPZYCJUADXRS-UHFFFAOYSA-M 4-fluoro-3-(trifluoromethyl)benzoate Chemical compound [O-]C(=O)C1=CC=C(F)C(C(F)(F)F)=C1 WZBPZYCJUADXRS-UHFFFAOYSA-M 0.000 claims description 3
- KTCMBLUJFHQKJL-OAHLLOKOSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 2,3-difluorobenzoate Chemical compound FC1=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=CC=C1F KTCMBLUJFHQKJL-OAHLLOKOSA-N 0.000 claims description 3
- YJVUUYULWBPESD-OAHLLOKOSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 2,5-difluorobenzoate Chemical compound FC1=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=C(C=C1)F YJVUUYULWBPESD-OAHLLOKOSA-N 0.000 claims description 3
- FLCOEPUOBVVIAQ-OAHLLOKOSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 2,6-difluorobenzoate Chemical compound FC1=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C(=CC=C1)F FLCOEPUOBVVIAQ-OAHLLOKOSA-N 0.000 claims description 3
- WDZGOXOEOHCWNT-OAHLLOKOSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 2-chloro-3-fluorobenzoate Chemical compound ClC1=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=CC=C1F WDZGOXOEOHCWNT-OAHLLOKOSA-N 0.000 claims description 3
- VRCXUHXKUREAJZ-OAHLLOKOSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 2-chloro-6-fluorobenzoate Chemical compound ClC1=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C(=CC=C1)F VRCXUHXKUREAJZ-OAHLLOKOSA-N 0.000 claims description 3
- QFDFQYORPFUCCB-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 2-ethylbutanoate Chemical compound C(C)C(C(=O)OC[C@@H](CN1N=C(C=2C(NCC3(CCOCC3)CC=21)=O)CC)C)CC QFDFQYORPFUCCB-MRXNPFEDSA-N 0.000 claims description 3
- YEYXLDOCLKMBGR-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 2-fluoro-3-methoxybenzoate Chemical compound FC1=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=CC=C1OC YEYXLDOCLKMBGR-MRXNPFEDSA-N 0.000 claims description 3
- IAATXXXRGANTCS-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 2-fluoro-4-methoxybenzoate Chemical compound FC1=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=CC(=C1)OC IAATXXXRGANTCS-MRXNPFEDSA-N 0.000 claims description 3
- WVSWGOOMRGGNGC-QGZVFWFLSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 2-fluoro-4-methylbenzoate Chemical compound FC1=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=CC(=C1)C WVSWGOOMRGGNGC-QGZVFWFLSA-N 0.000 claims description 3
- WXIISELCUMCXDS-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 2-fluoro-5-methoxybenzoate Chemical compound FC1=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=C(C=C1)OC WXIISELCUMCXDS-MRXNPFEDSA-N 0.000 claims description 3
- RMEYWEJUUAESNL-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 2-fluoro-6-methoxybenzoate Chemical compound FC1=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C(=CC=C1)OC RMEYWEJUUAESNL-MRXNPFEDSA-N 0.000 claims description 3
- MLPBAEAJTJCAIQ-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 2-fluoro-6-methylbenzoate Chemical compound FC1=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C(=CC=C1)C MLPBAEAJTJCAIQ-MRXNPFEDSA-N 0.000 claims description 3
- DZCKIELUOUTBRC-OAHLLOKOSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 2-methylpropanoate Chemical compound CC(C(=O)OC[C@@H](CN1N=C(C=2C(NCC3(CCOCC3)CC=21)=O)CC)C)C DZCKIELUOUTBRC-OAHLLOKOSA-N 0.000 claims description 3
- CZPRSLDNRSYNNG-OAHLLOKOSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 3,4-difluorobenzoate Chemical compound FC=1C=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=CC=1F CZPRSLDNRSYNNG-OAHLLOKOSA-N 0.000 claims description 3
- FAIJAUUNVKMDRQ-OAHLLOKOSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 3-chloro-2-fluorobenzoate Chemical compound ClC=1C(=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=CC=1)F FAIJAUUNVKMDRQ-OAHLLOKOSA-N 0.000 claims description 3
- RFJJXXPYGBOZGW-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 3-chloro-2-methoxybenzoate Chemical compound ClC=1C(=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=CC=1)OC RFJJXXPYGBOZGW-MRXNPFEDSA-N 0.000 claims description 3
- SLHHHRCIAZTHQD-OAHLLOKOSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 3-chloro-4-fluorobenzoate Chemical compound ClC=1C=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=CC=1F SLHHHRCIAZTHQD-OAHLLOKOSA-N 0.000 claims description 3
- HSXUCJRLPCCFND-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 3-chloro-4-methoxybenzoate Chemical compound ClC=1C=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=CC=1OC HSXUCJRLPCCFND-MRXNPFEDSA-N 0.000 claims description 3
- BCYXJDDVRJEAAY-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 3-cyano-4-fluorobenzoate Chemical compound C(#N)C=1C=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=CC=1F BCYXJDDVRJEAAY-MRXNPFEDSA-N 0.000 claims description 3
- FRHOAVVJUMJUJY-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 3-cyano-5-fluorobenzoate Chemical compound C(#N)C=1C=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=C(C=1)F FRHOAVVJUMJUJY-MRXNPFEDSA-N 0.000 claims description 3
- KBWDBXVDFZIKJV-QGZVFWFLSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 3-cyanobenzoate Chemical compound C(#N)C=1C=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=CC=1 KBWDBXVDFZIKJV-QGZVFWFLSA-N 0.000 claims description 3
- RYYBEFSOYFYIOB-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 3-fluoro-2-methoxybenzoate Chemical compound FC=1C(=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=CC=1)OC RYYBEFSOYFYIOB-MRXNPFEDSA-N 0.000 claims description 3
- WSYZQVGTAZKFDC-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 3-fluoro-4-methoxybenzoate Chemical compound FC=1C=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=CC=1OC WSYZQVGTAZKFDC-MRXNPFEDSA-N 0.000 claims description 3
- BDKZHDWXONRACA-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 3-fluorobenzoate Chemical compound FC=1C=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=CC=1 BDKZHDWXONRACA-MRXNPFEDSA-N 0.000 claims description 3
- UJYXJCDOXSJDNE-QGZVFWFLSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 3-methoxybenzoate Chemical compound COC=1C=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=CC=1 UJYXJCDOXSJDNE-QGZVFWFLSA-N 0.000 claims description 3
- NACFPQBPGMUWCJ-OAHLLOKOSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 4-chloro-2-fluorobenzoate Chemical compound ClC1=CC(=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=C1)F NACFPQBPGMUWCJ-OAHLLOKOSA-N 0.000 claims description 3
- FBXASJOOOSYFRZ-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 4-chloro-2-methoxybenzoate Chemical compound ClC1=CC(=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=C1)OC FBXASJOOOSYFRZ-MRXNPFEDSA-N 0.000 claims description 3
- IUUVLVOAHKUQHO-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 4-chloro-2-methylbenzoate Chemical compound ClC1=CC(=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=C1)C IUUVLVOAHKUQHO-MRXNPFEDSA-N 0.000 claims description 3
- GAHLFQRARSOHRS-OAHLLOKOSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 4-chloro-3-fluorobenzoate Chemical compound ClC1=C(C=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=C1)F GAHLFQRARSOHRS-OAHLLOKOSA-N 0.000 claims description 3
- WAFFFSLUBCHINL-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 4-chlorobenzoate Chemical compound ClC1=CC=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=C1 WAFFFSLUBCHINL-MRXNPFEDSA-N 0.000 claims description 3
- GMQCQEJIICLFOS-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 4-cyano-3-fluorobenzoate Chemical compound C(#N)C1=C(C=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=C1)F GMQCQEJIICLFOS-MRXNPFEDSA-N 0.000 claims description 3
- XEFXKTCGARQDSS-QGZVFWFLSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 4-cyanobenzoate Chemical compound C(#N)C1=CC=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=C1 XEFXKTCGARQDSS-QGZVFWFLSA-N 0.000 claims description 3
- HAMQDXMBSJNKBM-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 4-fluoro-2-methoxybenzoate Chemical compound FC1=CC(=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=C1)OC HAMQDXMBSJNKBM-MRXNPFEDSA-N 0.000 claims description 3
- CEWBKEQLSLDISI-QGZVFWFLSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 4-methoxy-3-methylbenzoate Chemical compound COC1=C(C=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=C1)C CEWBKEQLSLDISI-QGZVFWFLSA-N 0.000 claims description 3
- YYSYOMMLEHBYOD-OAHLLOKOSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 5-chloro-2-fluorobenzoate Chemical compound ClC=1C=CC(=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=1)F YYSYOMMLEHBYOD-OAHLLOKOSA-N 0.000 claims description 3
- VTMVJXRMZJHTFN-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 5-chloro-2-methoxybenzoate Chemical compound ClC=1C=CC(=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=1)OC VTMVJXRMZJHTFN-MRXNPFEDSA-N 0.000 claims description 3
- IUROTAIIAMLFRX-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 5-cyano-2-fluorobenzoate Chemical compound C(#N)C=1C=CC(=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=1)F IUROTAIIAMLFRX-MRXNPFEDSA-N 0.000 claims description 3
- RPALEWDVNRXSSJ-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 5-fluoro-2-methylbenzoate Chemical compound FC=1C=CC(=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=1)C RPALEWDVNRXSSJ-MRXNPFEDSA-N 0.000 claims description 3
- LYEFGIFXIOOZGG-QGZVFWFLSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] benzoate Chemical compound C(C1=CC=CC=C1)(=O)OC[C@@H](CN1N=C(C=2C(NCC3(CCOCC3)CC=21)=O)CC)C LYEFGIFXIOOZGG-QGZVFWFLSA-N 0.000 claims description 3
- VRNARGMXFRXSDS-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] cyclopentanecarboxylate Chemical compound C1(CCCC1)C(=O)OC[C@@H](CN1N=C(C=2C(NCC3(CCOCC3)CC=21)=O)CC)C VRNARGMXFRXSDS-MRXNPFEDSA-N 0.000 claims description 3
- BDKZHDWXONRACA-INIZCTEOSA-N [(2S)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 3-fluorobenzoate Chemical compound FC=1C=C(C(=O)OC[C@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=CC=1 BDKZHDWXONRACA-INIZCTEOSA-N 0.000 claims description 3
- UJYXJCDOXSJDNE-KRWDZBQOSA-N [(2S)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 3-methoxybenzoate Chemical compound COC=1C=C(C(=O)OC[C@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=CC=1 UJYXJCDOXSJDNE-KRWDZBQOSA-N 0.000 claims description 3
- WAFFFSLUBCHINL-INIZCTEOSA-N [(2S)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 4-chlorobenzoate Chemical compound ClC1=CC=C(C(=O)OC[C@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=C1 WAFFFSLUBCHINL-INIZCTEOSA-N 0.000 claims description 3
- ZCINQNHAYWWVDC-INIZCTEOSA-N [(2S)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 4-fluorobenzoate Chemical compound FC1=CC=C(C(=O)OC[C@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=C1 ZCINQNHAYWWVDC-INIZCTEOSA-N 0.000 claims description 3
- LYEFGIFXIOOZGG-KRWDZBQOSA-N [(2S)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] benzoate Chemical compound C(C1=CC=CC=C1)(=O)OC[C@H](CN1N=C(C=2C(NCC3(CCOCC3)CC=21)=O)CC)C LYEFGIFXIOOZGG-KRWDZBQOSA-N 0.000 claims description 3
- JBLQTPNTWOTOTM-UHFFFAOYSA-N [3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2,2-dimethylpropyl] 2-chloro-4-fluorobenzoate Chemical compound ClC1=C(C(=O)OCC(CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)(C)C)C=CC(=C1)F JBLQTPNTWOTOTM-UHFFFAOYSA-N 0.000 claims description 3
- JZYLTLQSPOQXFX-UHFFFAOYSA-N [3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2,2-dimethylpropyl] 2-chloro-6-fluorobenzoate Chemical compound ClC1=C(C(=O)OCC(CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)(C)C)C(=CC=C1)F JZYLTLQSPOQXFX-UHFFFAOYSA-N 0.000 claims description 3
- NTTZJOTXPURPFN-UHFFFAOYSA-N [3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2,2-dimethylpropyl] 2-chlorobenzoate Chemical compound ClC1=C(C(=O)OCC(CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)(C)C)C=CC=C1 NTTZJOTXPURPFN-UHFFFAOYSA-N 0.000 claims description 3
- UIQRYGMGELAIKG-UHFFFAOYSA-N [3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2,2-dimethylpropyl] 2-ethylbutanoate Chemical compound C(C)C(C(=O)OCC(CN1N=C(C=2C(NCC3(CCOCC3)CC=21)=O)CC)(C)C)CC UIQRYGMGELAIKG-UHFFFAOYSA-N 0.000 claims description 3
- FVKFKMSADNOZFE-UHFFFAOYSA-N [3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2,2-dimethylpropyl] 2-fluorobenzoate Chemical compound FC1=C(C(=O)OCC(CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)(C)C)C=CC=C1 FVKFKMSADNOZFE-UHFFFAOYSA-N 0.000 claims description 3
- BCVDRWRWEFDPIG-UHFFFAOYSA-N [3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2,2-dimethylpropyl] 3,4-difluorobenzoate Chemical compound FC=1C=C(C(=O)OCC(CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)(C)C)C=CC=1F BCVDRWRWEFDPIG-UHFFFAOYSA-N 0.000 claims description 3
- ZRTRKVSKACOCBU-UHFFFAOYSA-N [3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2,2-dimethylpropyl] 3,5-difluorobenzoate Chemical compound FC=1C=C(C(=O)OCC(CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)(C)C)C=C(C=1)F ZRTRKVSKACOCBU-UHFFFAOYSA-N 0.000 claims description 3
- XMWPWPQRKHWXHP-UHFFFAOYSA-N [3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2,2-dimethylpropyl] 3-chlorobenzoate Chemical compound ClC=1C=C(C(=O)OCC(CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)(C)C)C=CC=1 XMWPWPQRKHWXHP-UHFFFAOYSA-N 0.000 claims description 3
- NBBUQBSXKKAKAP-UHFFFAOYSA-N [3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2,2-dimethylpropyl] 3-cyanobenzoate Chemical compound C(#N)C=1C=C(C(=O)OCC(CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)(C)C)C=CC=1 NBBUQBSXKKAKAP-UHFFFAOYSA-N 0.000 claims description 3
- TWRAEPIJRSDEDA-UHFFFAOYSA-N [3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2,2-dimethylpropyl] 3-ethoxybenzoate Chemical compound C(C)OC=1C=C(C(=O)OCC(CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)(C)C)C=CC=1 TWRAEPIJRSDEDA-UHFFFAOYSA-N 0.000 claims description 3
- MRDCKQJWFUWQNE-UHFFFAOYSA-N [3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2,2-dimethylpropyl] 3-fluorobenzoate Chemical compound FC=1C=C(C(=O)OCC(CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)(C)C)C=CC=1 MRDCKQJWFUWQNE-UHFFFAOYSA-N 0.000 claims description 3
- GMBZUEZMPIJFAM-UHFFFAOYSA-N [3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2,2-dimethylpropyl] 3-methoxybenzoate Chemical compound COC=1C=C(C(=O)OCC(CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)(C)C)C=CC=1 GMBZUEZMPIJFAM-UHFFFAOYSA-N 0.000 claims description 3
- ZTWXPRYURRDKRX-UHFFFAOYSA-N [3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2,2-dimethylpropyl] 4-cyano-2-fluorobenzoate Chemical compound C(#N)C1=CC(=C(C(=O)OCC(CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)(C)C)C=C1)F ZTWXPRYURRDKRX-UHFFFAOYSA-N 0.000 claims description 3
- AQQOGOPZLCFXBI-UHFFFAOYSA-N [3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2,2-dimethylpropyl] 4-cyano-3-fluorobenzoate Chemical compound C(#N)C1=C(C=C(C(=O)OCC(CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)(C)C)C=C1)F AQQOGOPZLCFXBI-UHFFFAOYSA-N 0.000 claims description 3
- DLASZRFRKGLOTD-UHFFFAOYSA-N [3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2,2-dimethylpropyl] 4-cyanobenzoate Chemical compound C(#N)C1=CC=C(C(=O)OCC(CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)(C)C)C=C1 DLASZRFRKGLOTD-UHFFFAOYSA-N 0.000 claims description 3
- KFNYCNQYPREYNL-UHFFFAOYSA-N [3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2,2-dimethylpropyl] 4-fluorobenzoate Chemical compound FC1=CC=C(C(=O)OCC(CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)(C)C)C=C1 KFNYCNQYPREYNL-UHFFFAOYSA-N 0.000 claims description 3
- DAMNASPZDHKLBB-UHFFFAOYSA-N [3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2,2-dimethylpropyl] cyclopentanecarboxylate Chemical compound C1(CCCC1)C(=O)OCC(CN1N=C(C=2C(NCC3(CCOCC3)CC=21)=O)CC)(C)C DAMNASPZDHKLBB-UHFFFAOYSA-N 0.000 claims description 3
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N benzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 claims description 3
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 claims description 3
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 claims description 3
- 229940090181 propyl acetate Drugs 0.000 claims description 3
- YXHWFMQRECDLHQ-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 2-chloro-3-methoxybenzoate Chemical compound ClC1=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=CC=C1OC YXHWFMQRECDLHQ-MRXNPFEDSA-N 0.000 claims description 2
- JGWMBBXJZRXZLE-OAHLLOKOSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 2-chloro-5-fluorobenzoate Chemical compound ClC1=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=C(C=C1)F JGWMBBXJZRXZLE-OAHLLOKOSA-N 0.000 claims description 2
- ORTXUYXXNHSLLX-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 4-fluoro-3-methoxybenzoate Chemical compound FC1=C(C=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=C1)OC ORTXUYXXNHSLLX-MRXNPFEDSA-N 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- SOWDWUPMHVDZGL-UHFFFAOYSA-N 2-methoxy-4-methylbenzoic acid Chemical compound COC1=CC(C)=CC=C1C(O)=O SOWDWUPMHVDZGL-UHFFFAOYSA-N 0.000 claims 1
- OXUUNDMDOOXPKY-UHFFFAOYSA-M 4-chloro-3-methoxybenzoate Chemical compound COC1=CC(C([O-])=O)=CC=C1Cl OXUUNDMDOOXPKY-UHFFFAOYSA-M 0.000 claims 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-M 4-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-M 0.000 claims 1
- BBYDXOIZLAWGSL-UHFFFAOYSA-M 4-fluorobenzoate Chemical compound [O-]C(=O)C1=CC=C(F)C=C1 BBYDXOIZLAWGSL-UHFFFAOYSA-M 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- LXNFVVDCCWUUKC-UHFFFAOYSA-N methyl 4-chlorobenzoate Chemical compound COC(=O)C1=CC=C(Cl)C=C1 LXNFVVDCCWUUKC-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 4
- 229910003827 NRaRb Inorganic materials 0.000 abstract 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 114
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 114
- 239000000203 mixture Substances 0.000 description 109
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 83
- 239000000243 solution Substances 0.000 description 69
- 238000005481 NMR spectroscopy Methods 0.000 description 53
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 46
- 125000003118 aryl group Chemical group 0.000 description 42
- 238000004128 high performance liquid chromatography Methods 0.000 description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
- 235000002639 sodium chloride Nutrition 0.000 description 38
- 235000019439 ethyl acetate Nutrition 0.000 description 35
- 239000012453 solvate Substances 0.000 description 31
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 28
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 28
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 28
- 229910052796 boron Inorganic materials 0.000 description 27
- 239000002904 solvent Substances 0.000 description 27
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 25
- 238000007429 general method Methods 0.000 description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 230000014759 maintenance of location Effects 0.000 description 23
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 22
- 239000003480 eluent Substances 0.000 description 22
- 238000009472 formulation Methods 0.000 description 22
- 125000004093 cyano group Chemical group *C#N 0.000 description 21
- 239000007788 liquid Substances 0.000 description 21
- 239000011734 sodium Substances 0.000 description 21
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 19
- 150000001721 carbon Chemical group 0.000 description 19
- 238000004440 column chromatography Methods 0.000 description 19
- 239000007787 solid Substances 0.000 description 19
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 18
- 239000012267 brine Substances 0.000 description 18
- 239000012074 organic phase Substances 0.000 description 18
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 18
- 125000003003 spiro group Chemical group 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 16
- 239000003643 water by type Substances 0.000 description 16
- 239000002253 acid Substances 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 15
- 125000000217 alkyl group Chemical group 0.000 description 13
- 229940098779 methanesulfonic acid Drugs 0.000 description 13
- 239000003921 oil Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- 238000004587 chromatography analysis Methods 0.000 description 12
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 238000010898 silica gel chromatography Methods 0.000 description 11
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 10
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- 150000001412 amines Chemical class 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 8
- BFASPZFMEQRSGS-UHFFFAOYSA-N 9-propanoyl-3-oxaspiro[5.5]undecane-8,10-dione Chemical compound C(CC)(=O)C1C(CC2(CCOCC2)CC1=O)=O BFASPZFMEQRSGS-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 150000004677 hydrates Chemical class 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 239000004215 Carbon black (E152) Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 6
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 229930195733 hydrocarbon Natural products 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 5
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 5
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- GOUHYARYYWKXHS-UHFFFAOYSA-N 4-formylbenzoic acid Chemical compound OC(=O)C1=CC=C(C=O)C=C1 GOUHYARYYWKXHS-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
- 239000003810 Jones reagent Substances 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- UDEWPOVQBGFNGE-UHFFFAOYSA-N benzoic acid n-propyl ester Natural products CCCOC(=O)C1=CC=CC=C1 UDEWPOVQBGFNGE-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- WRTSXKKAXLYBSH-UHFFFAOYSA-N trifluoromethyl benzoate Chemical compound FC(F)(F)OC(=O)C1=CC=CC=C1 WRTSXKKAXLYBSH-UHFFFAOYSA-N 0.000 description 4
- RMHSHSPKDVFYCW-UHFFFAOYSA-N 3-ethyl-1-(3-hydroxypropyl)spiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-4-one Chemical compound C(C)C1=NN(C2=C1C(NCC1(CCOCC1)C2)=O)CCCO RMHSHSPKDVFYCW-UHFFFAOYSA-N 0.000 description 3
- BFBKRBFZGLBHMY-GFCCVEGCSA-N 3-ethyl-1-[(2R)-3-hydroxy-2-methylpropyl]spiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-4-one Chemical compound C(C)C1=NN(C2=C1C(NCC1(CCOCC1)C2)=O)C[C@H](CO)C BFBKRBFZGLBHMY-GFCCVEGCSA-N 0.000 description 3
- PRNSRLDFCKRWJY-UHFFFAOYSA-N 3-ethylspiro[5,7-dihydro-1H-indazole-6,4'-oxane]-4-one Chemical compound C(C)C1=NNC=2CC3(CCOCC3)CC(C1=2)=O PRNSRLDFCKRWJY-UHFFFAOYSA-N 0.000 description 3
- LZABGPVYVVCDRG-MRXNPFEDSA-N 4-[(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropoxy]carbonylbenzoic acid Chemical compound C(C)C1=NN(C2=C1C(NCC1(CCOCC1)C2)=O)C[C@H](COC(=O)C1=CC=C(C(=O)O)C=C1)C LZABGPVYVVCDRG-MRXNPFEDSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 description 3
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 3
- IOPHWDKDKDRVJA-UHFFFAOYSA-N (1-formylcyclopropyl)methyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1(C=O)CC1 IOPHWDKDKDRVJA-UHFFFAOYSA-N 0.000 description 2
- ZZFHBVUWNRIESU-UHFFFAOYSA-N (2,2-dimethyl-3-oxopropyl) benzoate Chemical compound O=CC(C)(C)COC(=O)C1=CC=CC=C1 ZZFHBVUWNRIESU-UHFFFAOYSA-N 0.000 description 2
- PDOWTVOYXCQNLY-UHFFFAOYSA-N (3-hydrazinyl-2,2-dimethylpropyl) benzoate Chemical compound C(C1=CC=CC=C1)(=O)OCC(CNN)(C)C PDOWTVOYXCQNLY-UHFFFAOYSA-N 0.000 description 2
- DKZFIPFKXAGEBP-UHFFFAOYSA-N (3-hydroxy-2,2-dimethylpropyl) benzoate Chemical compound OCC(C)(C)COC(=O)C1=CC=CC=C1 DKZFIPFKXAGEBP-UHFFFAOYSA-N 0.000 description 2
- YAEGMGMKLJYYJE-UHFFFAOYSA-N 1-(3,6-dihydro-2h-pyran-4-yl)propan-2-one Chemical compound CC(=O)CC1=CCOCC1 YAEGMGMKLJYYJE-UHFFFAOYSA-N 0.000 description 2
- SCUVHRLVYMCGDU-UHFFFAOYSA-N 1-(oxan-4-ylidene)propan-2-one Chemical compound CC(=O)C=C1CCOCC1 SCUVHRLVYMCGDU-UHFFFAOYSA-N 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- MWFMGBPGAXYFAR-UHFFFAOYSA-N 2-hydroxy-2-methylpropanenitrile Chemical compound CC(C)(O)C#N MWFMGBPGAXYFAR-UHFFFAOYSA-N 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- UHDNUPHSDMOGCR-UHFFFAOYSA-N 3-Formylbenzoic acid Chemical compound OC(=O)C1=CC=CC(C=O)=C1 UHDNUPHSDMOGCR-UHFFFAOYSA-N 0.000 description 2
- MVPPSDXFZIRVQE-MRXNPFEDSA-N 3-[(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropoxy]carbonylbenzoic acid Chemical compound C(C)C1=NN(C2=C1C(NCC1(CCOCC1)C2)=O)C[C@H](COC(=O)C=1C=C(C(=O)O)C=CC=1)C MVPPSDXFZIRVQE-MRXNPFEDSA-N 0.000 description 2
- AQTWNTDPBHSTKX-UHFFFAOYSA-N 3-[3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2,2-dimethylpropoxy]carbonylbenzoic acid Chemical compound C(C)C1=NN(C2=C1C(NCC1(CCOCC1)C2)=O)CC(COC(=O)C=1C=C(C(=O)O)C=CC=1)(C)C AQTWNTDPBHSTKX-UHFFFAOYSA-N 0.000 description 2
- JSUGFDAWJOXBGZ-UHFFFAOYSA-N 3-ethyl-1-(3-hydroxypropyl)spiro[5,7-dihydroindazole-6,4'-oxane]-4-one Chemical compound C(C)C1=NN(C=2CC3(CCOCC3)CC(C1=2)=O)CCCO JSUGFDAWJOXBGZ-UHFFFAOYSA-N 0.000 description 2
- IRNXAZQYGJLTCX-UHFFFAOYSA-N 3-ethyl-1-(4-hydroxybutyl)spiro[5,7-dihydroindazole-6,4'-oxane]-4-one Chemical compound C(C)C1=NN(C=2CC3(CCOCC3)CC(C1=2)=O)CCCCO IRNXAZQYGJLTCX-UHFFFAOYSA-N 0.000 description 2
- HIWANAVZZJFCNT-QRIPLOBPSA-N 3-ethyl-1-[(2R)-2-methyl-3-(oxan-2-yloxy)propyl]spiro[5,7-dihydroindazole-6,4'-oxane]-4-one Chemical compound C(C)C1=NN(C=2CC3(CCOCC3)CC(C1=2)=O)C[C@H](COC1OCCCC1)C HIWANAVZZJFCNT-QRIPLOBPSA-N 0.000 description 2
- GABOMMQDZNHBCB-GFCCVEGCSA-N 3-ethyl-1-[(2R)-3-hydroxy-2-methylpropyl]spiro[5,7-dihydroindazole-6,4'-oxane]-4-one Chemical compound C(C)C1=NN(C=2CC3(CCOCC3)CC(C1=2)=O)C[C@H](CO)C GABOMMQDZNHBCB-GFCCVEGCSA-N 0.000 description 2
- UHDNUPHSDMOGCR-UHFFFAOYSA-M 3-formylbenzoate Chemical compound [O-]C(=O)C1=CC=CC(C=O)=C1 UHDNUPHSDMOGCR-UHFFFAOYSA-M 0.000 description 2
- WMRXHQRDCIXTCD-UHFFFAOYSA-N 3-hydrazinylpropan-1-ol Chemical compound NNCCCO WMRXHQRDCIXTCD-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- FMSMKICETOXRTO-UHFFFAOYSA-N 4-[3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2,2-dimethylpropoxy]carbonylbenzoic acid Chemical compound C(C)C1=NN(C2=C1C(NCC1(CCOCC1)C2)=O)CC(COC(=O)C1=CC=C(C(=O)O)C=C1)(C)C FMSMKICETOXRTO-UHFFFAOYSA-N 0.000 description 2
- OGSRLZPOSWZTJY-UHFFFAOYSA-N 4-[4-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)butoxycarbonyl]benzoic acid Chemical compound C(C)C1=NN(C2=C1C(NCC1(CCOCC1)C2)=O)CCCCOC(=O)C1=CC=C(C(=O)O)C=C1 OGSRLZPOSWZTJY-UHFFFAOYSA-N 0.000 description 2
- GOUHYARYYWKXHS-UHFFFAOYSA-M 4-formylbenzoate Chemical compound [O-]C(=O)C1=CC=C(C=O)C=C1 GOUHYARYYWKXHS-UHFFFAOYSA-M 0.000 description 2
- FQKGONKJQQBWKD-UHFFFAOYSA-N 4-hydrazinylbutan-1-ol Chemical compound NNCCCCO FQKGONKJQQBWKD-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000988424 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4B Proteins 0.000 description 2
- NVAAQCYDYDGIDM-UHFFFAOYSA-N O(CC)C(=O)C1C2(CCOCC2)CC(=CC1=O)O Chemical compound O(CC)C(=O)C1C2(CCOCC2)CC(=CC1=O)O NVAAQCYDYDGIDM-UHFFFAOYSA-N 0.000 description 2
- 101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- JYFGXHLAJSZUFD-VEDVMXKPSA-N [(2R)-2-methyl-3-(oxan-2-yloxy)propyl]hydrazine Chemical compound C[C@H](CNN)COC1OCCCC1 JYFGXHLAJSZUFD-VEDVMXKPSA-N 0.000 description 2
- GBLYLBWIWFXFJW-GOSISDBHSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 2-methoxy-4-methylbenzoate Chemical compound COC1=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=CC(=C1)C GBLYLBWIWFXFJW-GOSISDBHSA-N 0.000 description 2
- HIMHFGIMVZLXHE-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 4-chloro-3-methoxybenzoate Chemical compound ClC1=C(C=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=C1)OC HIMHFGIMVZLXHE-MRXNPFEDSA-N 0.000 description 2
- ZCINQNHAYWWVDC-MRXNPFEDSA-N [(2R)-3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2-methylpropyl] 4-fluorobenzoate Chemical compound FC1=CC=C(C(=O)OC[C@@H](CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)C)C=C1 ZCINQNHAYWWVDC-MRXNPFEDSA-N 0.000 description 2
- YTILDMRCCHITRH-RGURZIINSA-N [(2S)-2-methyl-3-(oxan-2-yloxy)propyl] methanesulfonate Chemical compound CS(=O)(=O)OC[C@H](COC1OCCCC1)C YTILDMRCCHITRH-RGURZIINSA-N 0.000 description 2
- AVOOZGMVIQZJQM-UHFFFAOYSA-N [1-(hydroxymethyl)cyclopropyl]methyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1(CO)CC1 AVOOZGMVIQZJQM-UHFFFAOYSA-N 0.000 description 2
- RKASLGHLNYLYMG-UHFFFAOYSA-N [1-[[tert-butyl(diphenyl)silyl]oxymethyl]cyclopropyl]methanol Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)OCC1(CO)CC1 RKASLGHLNYLYMG-UHFFFAOYSA-N 0.000 description 2
- LWDFPXKBXHABES-UHFFFAOYSA-N [1-[[tert-butyl(diphenyl)silyl]oxymethyl]cyclopropyl]methyl benzoate Chemical compound CC(C)(C)[Si](OCC1(COC(=O)C2=CC=CC=C2)CC1)(C1=CC=CC=C1)C1=CC=CC=C1 LWDFPXKBXHABES-UHFFFAOYSA-N 0.000 description 2
- ZANYCOXKOGISJP-UHFFFAOYSA-N [2,2-dimethyl-3-[2-[(2-methylpropan-2-yl)oxycarbonyl]hydrazinyl]propyl] benzoate Chemical compound C(C1=CC=CC=C1)(=O)OCC(CNNC(=O)OC(C)(C)C)(C)C ZANYCOXKOGISJP-UHFFFAOYSA-N 0.000 description 2
- PLUHCSXKMUJFDS-UHFFFAOYSA-N [3-(3-ethyl-4-oxospiro[5,7-dihydroindazole-6,4'-oxane]-1-yl)-2,2-dimethylpropyl] benzoate Chemical compound C(C1=CC=CC=C1)(=O)OCC(CN1N=C(C=2C(CC3(CCOCC3)CC1=2)=O)CC)(C)C PLUHCSXKMUJFDS-UHFFFAOYSA-N 0.000 description 2
- PMNIOACXCQNPEE-UHFFFAOYSA-N [3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2,2-dimethylpropyl] 4-chlorobenzoate Chemical compound ClC1=CC=C(C(=O)OCC(CN2N=C(C=3C(NCC4(CCOCC4)CC=32)=O)CC)(C)C)C=C1 PMNIOACXCQNPEE-UHFFFAOYSA-N 0.000 description 2
- IJLWWSYACPZGMI-UHFFFAOYSA-N [3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)-2,2-dimethylpropyl] benzoate Chemical compound C(C1=CC=CC=C1)(=O)OCC(CN1N=C(C=2C(NCC3(CCOCC3)CC=21)=O)CC)(C)C IJLWWSYACPZGMI-UHFFFAOYSA-N 0.000 description 2
- SESXZSLSTRITGO-UHFFFAOYSA-N [3-(bromomethyl)oxetan-3-yl]methanol Chemical compound OCC1(CBr)COC1 SESXZSLSTRITGO-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- 102100029168 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Human genes 0.000 description 2
- 102100029170 cAMP-specific 3',5'-cyclic phosphodiesterase 4D Human genes 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- DFBKLUNHFCTMDC-PICURKEMSA-N dieldrin Chemical compound C([C@H]1[C@H]2[C@@]3(Cl)C(Cl)=C([C@]([C@H]22)(Cl)C3(Cl)Cl)Cl)[C@H]2[C@@H]2[C@H]1O2 DFBKLUNHFCTMDC-PICURKEMSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 125000005879 dioxolanyl group Chemical group 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- LDQFGTRJWJHKMF-IENPIDJESA-N methyl (2s)-2-methyl-3-(oxan-2-yloxy)propanoate Chemical compound COC(=O)[C@@H](C)COC1CCCCO1 LDQFGTRJWJHKMF-IENPIDJESA-N 0.000 description 2
- ATCCIZURPPEVIZ-BYPYZUCNSA-N methyl (2s)-3-hydroxy-2-methylpropanoate Chemical compound COC(=O)[C@@H](C)CO ATCCIZURPPEVIZ-BYPYZUCNSA-N 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000007908 nanoemulsion Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- LPNBBFKOUUSUDB-UHFFFAOYSA-N p-toluic acid Chemical compound CC1=CC=C(C(O)=O)C=C1 LPNBBFKOUUSUDB-UHFFFAOYSA-N 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000010956 selective crystallization Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 1
- VGUJHMVGARVIAE-UHFFFAOYSA-N (10-oxo-3-oxaspiro[5.5]undec-8-en-8-yl) propanoate Chemical compound C(CC)(=O)OC=1CC2(CCOCC2)CC(C=1)=O VGUJHMVGARVIAE-UHFFFAOYSA-N 0.000 description 1
- JXKZGAOHTFCZQL-VEDVMXKPSA-N (2r)-2-methyl-3-(oxan-2-yloxy)propan-1-ol Chemical compound OC[C@@H](C)COC1CCCCO1 JXKZGAOHTFCZQL-VEDVMXKPSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- ZQXCQTAELHSNAT-UHFFFAOYSA-N 1-chloro-3-nitro-5-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(Cl)=CC(C(F)(F)F)=C1 ZQXCQTAELHSNAT-UHFFFAOYSA-N 0.000 description 1
- UOWIYNWMROWVDG-UHFFFAOYSA-N 1-dimethoxyphosphorylpropan-2-one Chemical compound COP(=O)(OC)CC(C)=O UOWIYNWMROWVDG-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- CHUGKEQJSLOLHL-UHFFFAOYSA-N 2,2-Bis(bromomethyl)propane-1,3-diol Chemical compound OCC(CO)(CBr)CBr CHUGKEQJSLOLHL-UHFFFAOYSA-N 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- VIUDWLLKFANPLX-UHFFFAOYSA-N 2-chloro-3-methoxybenzoic acid Chemical compound COC1=CC=CC(C(O)=O)=C1Cl VIUDWLLKFANPLX-UHFFFAOYSA-N 0.000 description 1
- MIZKCMSSYVUZKD-UHFFFAOYSA-N 2-chloro-5-fluorobenzoic acid Chemical compound OC(=O)C1=CC(F)=CC=C1Cl MIZKCMSSYVUZKD-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- UOGBEYUGWSLQPN-UHFFFAOYSA-N 3-[3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)propoxycarbonyl]benzoic acid Chemical compound C(C)C1=NN(C2=C1C(NCC1(CCOCC1)C2)=O)CCCOC(=O)C=1C=C(C(=O)O)C=CC=1 UOGBEYUGWSLQPN-UHFFFAOYSA-N 0.000 description 1
- LAMUXTNQCICZQX-UHFFFAOYSA-N 3-chloropropan-1-ol Chemical compound OCCCCl LAMUXTNQCICZQX-UHFFFAOYSA-N 0.000 description 1
- INJGGURVYQRWDJ-UHFFFAOYSA-N 3-ethyl-1-(4-hydroxybutyl)spiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-4-one Chemical compound C(C)C1=NN(C2=C1C(NCC1(CCOCC1)C2)=O)CCCCO INJGGURVYQRWDJ-UHFFFAOYSA-N 0.000 description 1
- JGSIAOZAXBWRFO-UHFFFAOYSA-N 3-methylsulfanyl-1-phenyl-4,5-dihydrobenzo[g]indazole Chemical compound C1CC2=CC=CC=C2C2=C1C(SC)=NN2C1=CC=CC=C1 JGSIAOZAXBWRFO-UHFFFAOYSA-N 0.000 description 1
- DGVPSAQTQGLBAM-UHFFFAOYSA-N 4-(dimethylsulfamoyl)benzoic acid Chemical compound CN(C)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DGVPSAQTQGLBAM-UHFFFAOYSA-N 0.000 description 1
- PAOYGUDKABVANA-UHFFFAOYSA-N 4-(methylsulfamoyl)benzoic acid Chemical compound CNS(=O)(=O)C1=CC=C(C(O)=O)C=C1 PAOYGUDKABVANA-UHFFFAOYSA-N 0.000 description 1
- ZQVKTHRQIXSMGY-UHFFFAOYSA-N 4-Ethylbenzoic acid Chemical compound CCC1=CC=C(C(O)=O)C=C1 ZQVKTHRQIXSMGY-UHFFFAOYSA-N 0.000 description 1
- PQECFINTROFWTE-UHFFFAOYSA-N 4-[3-(3-ethyl-4-oxospiro[6,8-dihydro-5H-pyrazolo[4,3-c]azepine-7,4'-oxane]-1-yl)propoxycarbonyl]benzoic acid Chemical compound C(C)C1=NN(C2=C1C(NCC1(CCOCC1)C2)=O)CCCOC(=O)C1=CC=C(C(=O)O)C=C1 PQECFINTROFWTE-UHFFFAOYSA-N 0.000 description 1
- OSFGNTLIOUHOKN-UHFFFAOYSA-N 4-[benzyl(methyl)sulfamoyl]benzoic acid Chemical compound C=1C=C(C(O)=O)C=CC=1S(=O)(=O)N(C)CC1=CC=CC=C1 OSFGNTLIOUHOKN-UHFFFAOYSA-N 0.000 description 1
- HXHGULXINZUGJX-UHFFFAOYSA-N 4-chlorobutanol Chemical compound OCCCCCl HXHGULXINZUGJX-UHFFFAOYSA-N 0.000 description 1
- LWGCZCMLPRMKIZ-UHFFFAOYSA-N 4-fluoro-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1F LWGCZCMLPRMKIZ-UHFFFAOYSA-N 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- RJBSTXIIQYFNPX-UHFFFAOYSA-N 4-methoxy-6-phenyl-1,3,5-triazin-2-amine Chemical compound COC1=NC(N)=NC(C=2C=CC=CC=2)=N1 RJBSTXIIQYFNPX-UHFFFAOYSA-N 0.000 description 1
- AJBWNNKDUMXZLM-UHFFFAOYSA-N 4-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=C(C(O)=O)C=C1 AJBWNNKDUMXZLM-UHFFFAOYSA-N 0.000 description 1
- WVEVFRXXOGKMHJ-UHFFFAOYSA-N 5,6-dihydro-1h-pyrazolo[3,4-e][1,4]diazepin-4-one Chemical class O=C1NCC=NC2=C1C=NN2 WVEVFRXXOGKMHJ-UHFFFAOYSA-N 0.000 description 1
- YZSCPLGKKMSBMV-UHFFFAOYSA-N 5-fluoro-4-(8-fluoro-4-propan-2-yl-2,3-dihydro-1,4-benzoxazin-6-yl)-N-[5-(1-methylpiperidin-4-yl)pyridin-2-yl]pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)C1CCN(CC1)C)C1=CC2=C(OCCN2C(C)C)C(=C1)F YZSCPLGKKMSBMV-UHFFFAOYSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- OIRPAOLBLXXMIL-UHFFFAOYSA-N 8-hydroxy-3-oxaspiro[5.5]undec-8-en-10-one Chemical compound OC=1CC2(CCOCC2)CC(C=1)=O OIRPAOLBLXXMIL-UHFFFAOYSA-N 0.000 description 1
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 101100096578 Arabidopsis thaliana SQD2 gene Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100407335 Dictyostelium discoideum pde7 gene Proteins 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 101100407340 Drosophila melanogaster Pde8 gene Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022491 Insulin resistant diabetes Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100407337 Mus musculus Pde8a gene Proteins 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- UULYVBBLIYLRCU-UHFFFAOYSA-N Palmitinsaeure-n-tetradecylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC UULYVBBLIYLRCU-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- YAINYZJQSQEGND-UHFFFAOYSA-N [1-(hydroxymethyl)cyclopropyl]methanol Chemical compound OCC1(CO)CC1 YAINYZJQSQEGND-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 229940092782 bentonite Drugs 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 150000007516 brønsted-lowry acids Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 108010021848 cyclosomatostatin Proteins 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- HZZRIIPYFPIKHR-UHFFFAOYSA-N ethyl 2-hydrazinylacetate;hydron;chloride Chemical compound Cl.CCOC(=O)CNN HZZRIIPYFPIKHR-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940067594 flufenamate Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000002343 gold Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 102000048135 human PDE4D Human genes 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- JUINSXZKUKVTMD-UHFFFAOYSA-N hydrogen azide Chemical compound N=[N+]=[N-] JUINSXZKUKVTMD-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000003041 laboratory chemical Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- DOWVMJFBDGWVML-UHFFFAOYSA-N n-cyclohexyl-n-methyl-4-(1-oxidopyridin-1-ium-3-yl)imidazole-1-carboxamide Chemical compound C1=NC(C=2C=[N+]([O-])C=CC=2)=CN1C(=O)N(C)C1CCCCC1 DOWVMJFBDGWVML-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
- KFDSUDXOCFQKIN-UHFFFAOYSA-N propyl 2-ethylbutanoate Chemical compound CCCOC(=O)C(CC)CC KFDSUDXOCFQKIN-UHFFFAOYSA-N 0.000 description 1
- CNKQUOBXOUMRJY-UHFFFAOYSA-N propyl 4-pyrrolidin-1-ylsulfonylbenzoate Chemical compound N1(CCCC1)S(=O)(=O)C1=CC=C(C(=O)OCCC)C=C1 CNKQUOBXOUMRJY-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- JAQJOJXZXMYDFO-UHFFFAOYSA-N pyrazolo[4,3-d]diazepine Chemical class N1=NC=C2C1=CC=NN=C2 JAQJOJXZXMYDFO-UHFFFAOYSA-N 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- ATCCIZURPPEVIZ-SCSAIBSYSA-N roche ester Chemical compound COC(=O)[C@H](C)CO ATCCIZURPPEVIZ-SCSAIBSYSA-N 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 1
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2016/080548 WO2018108230A1 (en) | 2016-12-12 | 2016-12-12 | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019121006A RU2019121006A (ru) | 2021-01-12 |
| RU2019121006A3 RU2019121006A3 (https=) | 2021-01-12 |
| RU2762279C2 true RU2762279C2 (ru) | 2021-12-17 |
Family
ID=57539258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019121006A RU2762279C2 (ru) | 2016-12-12 | 2016-12-12 | Замещенные пиразолоазепин-4-оны и их применение в качестве ингибиторов фосфодиэстеразы |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10906915B2 (https=) |
| EP (1) | EP3551633B1 (https=) |
| JP (1) | JP6850886B2 (https=) |
| CN (1) | CN110088108B (https=) |
| DK (1) | DK3551633T3 (https=) |
| ES (1) | ES2875128T3 (https=) |
| RU (1) | RU2762279C2 (https=) |
| WO (1) | WO2018108230A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3551632B1 (en) * | 2016-12-12 | 2024-06-12 | UNION therapeutics A/S | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors |
| DK3642210T3 (da) | 2017-06-20 | 2024-12-09 | Union Therapeutics As | Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser |
| PT3724196T (pt) | 2017-12-15 | 2023-01-13 | Union Therapeutics As | Azetidina di-hidrotienopiridinas substituídas e a sua utilização como inibidores de fosfodiesterase |
| GB202306662D0 (en) | 2023-05-05 | 2023-06-21 | Union Therapeutics As | Dosage regimen |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA005071B1 (ru) * | 2000-01-05 | 2004-10-28 | Уорнер-Ламберт Компани | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[4,3-e]ДИАЗЕПИНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ИХ, И ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ ПРОДУКТОВ |
| WO2007040435A1 (en) * | 2005-10-03 | 2007-04-12 | Astrazeneca Ab | Novel 5,6-dihydropyrazolo[3,4-e] [l,4]diazepin-4 (ih) -one derivatives for the treatment of asthma and chronic obstructive pulmonary disease. |
| WO2008104175A2 (en) * | 2007-02-28 | 2008-09-04 | Leo Pharma A/S | Novel phosphodiesterase inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004098520A2 (en) | 2003-05-01 | 2004-11-18 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| ES2372320T3 (es) | 2006-11-15 | 2012-01-18 | Vertex Pharmceuticals Incorporated | Compuestos útiles como inhibidores de proteínas quinasas. |
| GB0704652D0 (en) | 2007-03-09 | 2007-04-18 | Syngenta Participations Ag | Novel herbicides |
| AR084070A1 (es) * | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
-
2016
- 2016-12-12 JP JP2019531209A patent/JP6850886B2/ja not_active Expired - Fee Related
- 2016-12-12 DK DK16809388.8T patent/DK3551633T3/da active
- 2016-12-12 WO PCT/EP2016/080548 patent/WO2018108230A1/en not_active Ceased
- 2016-12-12 US US16/468,420 patent/US10906915B2/en active Active
- 2016-12-12 ES ES16809388T patent/ES2875128T3/es active Active
- 2016-12-12 RU RU2019121006A patent/RU2762279C2/ru active
- 2016-12-12 EP EP16809388.8A patent/EP3551633B1/en active Active
- 2016-12-12 CN CN201680091502.7A patent/CN110088108B/zh not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA005071B1 (ru) * | 2000-01-05 | 2004-10-28 | Уорнер-Ламберт Компани | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[4,3-e]ДИАЗЕПИНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ИХ, И ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ ПРОДУКТОВ |
| WO2007040435A1 (en) * | 2005-10-03 | 2007-04-12 | Astrazeneca Ab | Novel 5,6-dihydropyrazolo[3,4-e] [l,4]diazepin-4 (ih) -one derivatives for the treatment of asthma and chronic obstructive pulmonary disease. |
| WO2008104175A2 (en) * | 2007-02-28 | 2008-09-04 | Leo Pharma A/S | Novel phosphodiesterase inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110088108A (zh) | 2019-08-02 |
| RU2019121006A (ru) | 2021-01-12 |
| US20200010477A1 (en) | 2020-01-09 |
| US10906915B2 (en) | 2021-02-02 |
| RU2019121006A3 (https=) | 2021-01-12 |
| JP6850886B2 (ja) | 2021-03-31 |
| JP2020500920A (ja) | 2020-01-16 |
| CN110088108B (zh) | 2024-06-14 |
| DK3551633T3 (da) | 2021-06-28 |
| EP3551633A1 (en) | 2019-10-16 |
| EP3551633B1 (en) | 2021-03-31 |
| ES2875128T3 (es) | 2021-11-08 |
| WO2018108230A1 (en) | 2018-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2583787C2 (ru) | Гетероциклические соединения бензодиоксола или бензодиоксепина в качестве ингибиторов фосфодиэстераз | |
| JP7198820B2 (ja) | 置換アゼチジンジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用 | |
| JP7201688B2 (ja) | 置換テトラヒドロピランジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用 | |
| RU2762279C2 (ru) | Замещенные пиразолоазепин-4-оны и их применение в качестве ингибиторов фосфодиэстеразы | |
| EP3724196B9 (en) | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors | |
| CN111108109A (zh) | 取代的二氢噻吩并嘧啶及其作为磷酸二酯酶抑制剂的用途 | |
| CN104011048B (zh) | 作为磷酸二酯酶抑制剂的[1,2,4]三唑并吡啶类化合物及其应用 | |
| JP7008073B2 (ja) | 置換ピラゾロアゼピン-4-オンおよびそれらのホスホジエステラーゼ阻害剤としての使用 | |
| RU2764273C2 (ru) | Замещенные пиразолоазепин-8-оны и их применение в качестве ингибиторов фосфодиэстеразы | |
| HK40041147B (en) | Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant |